Sugi Predict

Sugi Predict / Compounds / SCHEMBL644676

SCHEMBL644676

SCHEMBL644676

c1cc(C2CCCC2)n[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ HAO1 Q9UJM8 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSP90AB1 P08238 1/20 0.33
▸ NOTUM Q6P988 1/20 0.32
▸ MIF P14174 1/20 0.32
▸ HCAR2 Q8TDS4 1/20 0.32
▸ CYP11B2 P19099 1/20 0.31
▸ JAK2 O60674 3/20 0.31
▸ JAK1 P23458 3/20 0.31
▸ JAK3 P52333 3/20 0.31
▸ CYP19A1 P11511 2/20 0.31
▸ KMO O15229 1/20 0.31
▸ DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL389567 0.98 KMT2A (0.38) HRH4KMT2AHAO1LMNAMIF
SCHEMBL2765846 0.98 KMT2A (0.38) HRH4KMT2AHAO1LMNAMIF
SCHEMBL2382277 0.98 KMT2A (0.38) HRH4KMT2AHAO1LMNAMIF
SCHEMBL30463126 0.98 KMT2A (0.38) HRH4KMT2AHAO1LMNAMIF
Water SCHEMBL2398687 0.96 KMT2A (0.37) HRH4KMT2AHAO1LMNAMIF
SCHEMBL27742479 0.96 KMT2A (0.37) HRH4KMT2AHAO1LMNAMIF
SCHEMBL27721928 0.96 KMT2A (0.37) HRH4KMT2AHAO1LMNAMIF
SCHEMBL2633370 0.95 — —
SCHEMBL1608843 0.91 — —
SCHEMBL30864882 0.84 ESR2 (0.38) KMT2AHAO1RAB9ANOTUMKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293381-A1 Therapeutic Compounds CELGENE QUANTICEL RES INC (US) 2024-09-05 — — US claimed
US-20210205284-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-07-08 — — US claimed
US-20200163946-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-28 — — US claimed
US-10617680-B2 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. (US) 2020-04-14 — — US claimed
EP-3612522-A1 THERAPEUTIC COMPOUNDS Celgene Quanticel Research, Inc. (US) 2020-02-26 — — EP claimed
WO-2018195155-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-10-25 — — WO claimed
US-20180296543-A1 THERAPEUTIC COMPOUNDS CELGENE QUANTICEL RESEARCH, INC. 2018-10-18 — — US claimed
US-12590125-B2 Peptide inhibitors for the inhibition of HIV capsid THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2026-03-31 — — US disclosed
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof TERREMOTO BIOSCIENCES, INC. (US) 2026-03-10 — — US disclosed
WO-2025081045-A9 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-12-26 — — WO disclosed
CN-121064037-A Preparation method of 1H-pyrazol-3-yl-cyclopentane derivative 正大天晴药业集团股份有限公司 2025-12-05 — — CN disclosed
CN-121064037-A Preparation method of 1H-pyrazol-3-yl-cyclopentane derivative 正大天晴药业集团股份有限公司 2025-12-05 — — CN disclosed
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 — — US disclosed
EP-1937646-A1 TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 — — EP disclosed
US-20070191362-A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-16 — — US disclosed
US-20070191362-A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-16 — — US disclosed
US-20070191362-A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2007-08-16 — — US disclosed
WO-2007035945-A1 TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-29 — — WO disclosed
WO-2007035945-A1 TETRAHYDRO-CYCLOPENTYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-29 — — WO disclosed
CN-1835953-A 4-Cycloalkylaminopyrazolopyrimidine NMDA/NR2B antagonists MERCK & CO INC (US) 2006-09-20 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293381-A1 Therapeutic Compounds EP300, BRD4, BRD3 HRH4 2273/4885KMT2A 84/4885HAO1 4752/4885
US-20200163946-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HRH4 2273/4885KMT2A 84/4885HAO1 4752/4885
US-12570655-B2 Cysteine covalent modifiers of AKT1 and uses thereof AKT1, AKT2, AKT3 HRH4 3571/4885KMT2A 1229/4885HAO1 2613/4885
US-20070191362-A1 Tetrahydro-cyclopentyl pyrazole cannabinoid modulators CNR1, CNR2, GPR18 HRH4 111/4885KMT2A 2784/4885HAO1 4579/4885
US-20180296543-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HRH4 2273/4885KMT2A 84/4885HAO1 4752/4885
US-20250289819-A1 CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT2, AKT3 HRH4 4649/4885KMT2A 932/4885HAO1 3993/4885
US-12590125-B2 Peptide inhibitors for the inhibition of HIV capsid VIP, QPCT, TPX2 HRH4 4123/4885KMT2A 1300/4885HAO1 4704/4885
US-20210205284-A1 THERAPEUTIC COMPOUNDS EP300, BRD4, BRD3 HRH4 2273/4885KMT2A 84/4885HAO1 4752/4885
US-10617680-B2 Therapeutic compounds EP300, BRD4, BRD3 HRH4 2273/4885KMT2A 84/4885HAO1 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.